We will use the drug J113863, a CCR1/3 receptor antagonist. Mitra and colleagues showed that this drug successfully blocked the homing of ovarian cancer cells to normal omental fibroblasts transfected with anti-miR-214 and anti-miR-31- an induced CAF phenotype. We will deliver this on the biopolymer sheet. The biopolymer sheet will be put directly on the omentum during surgery. This delivery method will allow introduction of the drug directly on its target - the omental fibroblasts and any metastatic cancer cells. CCL5 will be unable to bind to its receptor and therefore the receptor will not transduce the signal to the NF-kB signaling pathway, which therefore will inhibit the epithelial to mesenchymal transition of ovarian cancer cells.
Recent comments